BLOG

New DEA Guidance On Quantitative Thresholds

New DEA Guidance On Quantitative Thresholds

Guidance On Quantitative Thresholds Written-by: Deneen Fumich, RPh As the Pharmaceutical Supply Chain continues to digest the Injunctive Relief requirements for the Big 3 Wholesalers, questions have been posed by industry to both the DEA and State Regulators as to the...

read more
Drug Price Transparency
The Increasing Trend of Drug Price Transparency

Drug Pricing Transparency Fight Rages On

Even as the COVID-19 pandemic disrupts day-to-day life, drug pricing transparency rages on between consumer groups, regulators, and industry. Regulators are now having to resort to assessing significant fines to increase compliance.

read more
2020 Update: Continuing Pressure on Drug Manufacturers

2020 Update: Continuing Pressure on Drug Manufacturers

With the developments around COVID-19, the drug manufacturers that working on a cure for the virus have been praised as (potential) saviors across the globe. This is a stark change to how they have regarded over the last few years – drug manufacturers have faced significant scrutiny due to a variety of issues including the opioid epidemic, generic price-fixing and price increases.

read more

Email Newsletter